Sugi Predict

Sugi Predict / Compounds / SCHEMBL657486

SCHEMBL657486

SCHEMBL657486

CN1CCC(n2cc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.44
▸ GAA P10253 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ IRAK4 Q9NWZ3 10/20 0.36
▸ FLT3 P36888 3/20 0.36
▸ GSK3B P49841 3/20 0.36
▸ DYRK1A Q13627 3/20 0.36
▸ ALOX15 P16050 1/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ IKBKE Q14164 1/20 0.34
▸ TBK1 Q9UHD2 1/20 0.34
▸ CLK2 P49760 1/20 0.34
▸ CLK3 P49761 1/20 0.34
▸ PIK3CD O00329 2/20 0.34
▸ NTRK1 P04629 2/20 0.34
▸ IRAK1 P51617 2/20 0.34
▸ NTRK3 Q16288 2/20 0.34
▸ NTRK2 Q16620 2/20 0.34
▸ BTK Q06187 1/20 0.33
▸ MET P08581 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21426239 0.92 FFAR1 (0.42) FFAR1GAASMN1; SMN2IRAK4FLT3
SCHEMBL21588639 0.91 FFAR1 (0.40) FFAR1GAASMN1; SMN2IRAK4FLT3
SCHEMBL30566117 0.91 FFAR1 (0.41) FFAR1IRAK4FLT3GSK3BDYRK1A
SCHEMBL1987497 0.90 FFAR1 (0.49) FFAR1IRAK4
Methyl Alcohol SCHEMBL28336982 0.90 FFAR1 (0.43) FFAR1GAASMN1; SMN2IRAK4FLT3
SCHEMBL28649940 0.88 FFAR1 (0.46) FFAR1
SCHEMBL9100609 0.88 FFAR1 (0.43) FFAR1IRAK4GSK3BDYRK1A
SCHEMBL2572488 0.87 FFAR1 (0.47) FFAR1IRAK4CLK2
SCHEMBL2517121 0.87 FFAR1 (0.47) FFAR1IRAK4
SCHEMBL2749177 0.86 FFAR1 (0.46) FFAR1IRAK4BMPR1AACVRL1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 — — EP disclosed
EP-4712969-A1 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2026-03-25 — — EP disclosed
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2026-02-17 — — US disclosed
EP-4626423-A1 CDK INHIBITORS AND METHODS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-10-08 — — EP disclosed
US-12428420-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2025-09-30 — — US disclosed
EP-3653626-B1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DAEWOONG PHARMACEUTICAL CO LTD (KR) 2025-09-17 — — EP disclosed
US-20250270213-A1 PI3Ka INHIBITORS PIKAVATION THERAPEUTICS, INC. 2025-08-28 — — US disclosed
WO-2025124429-A1 AROMATIC AMINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京康辰药业股份有限公司 2025-06-19 — — WO disclosed
CN-116472047-B Arylamine derivative, preparation method and medical application thereof 中国医药研究开发中心有限公司 2025-06-17 — — CN disclosed
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 — — US disclosed
EP-2531500-A1 HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2012-12-12 — — EP disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 — — US disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 — — US disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 — — US disclosed
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-05-10 — — US disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 — — US disclosed
WO-2011100502-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2011-08-18 — — WO disclosed
WO-2011095196-A1 HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-08-11 — — WO disclosed
WO-2011095196-A1 HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-08-11 — — WO disclosed
US-20100063031-A1 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2010-03-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179059-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA FFAR1 4746/4885GAA 953/4885SMN1; SMN2 4326/4885
US-12428420-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 FFAR1 1699/4885GAA 426/4885SMN1; SMN2 4438/4885
US-20100063031-A1 KINASE INHIBITOR COMPOUNDS MAP4K2, MAP3K5, MAP3K15 FFAR1 4647/4885GAA 2316/4885SMN1; SMN2 3111/4885
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 FFAR1 2193/4885GAA 2419/4885SMN1; SMN2 1807/4885
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES PDK1, PDK2, PDK4 FFAR1 1676/4885GAA 3139/4885SMN1; SMN2 2413/4885
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 FFAR1 1016/4885GAA 2760/4885SMN1; SMN2 3900/4885
US-20250270213-A1 PI3Ka INHIBITORS PIK3CA, PIK3C2A, PIK3R5 FFAR1 3116/4885GAA 283/4885SMN1; SMN2 1804/4885
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives ATP5F1A, ATP5ME, ATP5F1D FFAR1 2973/4885GAA 885/4885SMN1; SMN2 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.